JPMorgan Downgrades Jounce Therapeutics (JNCE) to Neutral
JPMorgan downgraded Jounce Therapeutics (NASDAQ: JNCE) from Overweight to Neutral with a price target of $12.00 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)